沛嘉醫療-B(09996.HK)2024年業績亮眼:收入增長39.5%,TAVR與神經介入業務雙增長
格隆匯3月26日丨沛嘉醫療-B(09996.HK)發佈公告,截至2024年12月31日止年度,集團於報告期內的收入爲人民幣6.15億元,較2023年增加39.5%。收入構成保持穩定,其中42.2%來自TAVR相關產品銷售,57.8%來自神經介入產品銷售(2023年:分別爲42.1%及57.9%)。收入的強勁增長主要由於經導管瓣膜治療業務及神經介入業務的高銷售增長。
TAVR相關產品在報告期內的銷售收入同比增加40.1%至人民幣2.60億元,主要得益於集團在中國經股TAVR市場份額的擴大。於報告期內,終端植入總量超過3,400臺,同比增長約37%,而集團在中國經股TAVR市場份額提升至約25%。
神經介入產品在報告期內的銷售收入同比增加39.1%至人民幣3.56億元,主要得益於手術滲透率的提高、集團在帶量採購中的成功中標,以及集團完整的產品管線及有效的營銷策略。主要驅動因素包括:(i)DCwire®微導絲在全國範圍內的首年成功推出,得到了用戶的積極反饋和市場的廣泛採用;(ii)集團現有優勢產品Syphonet®取栓支架及Fastunnel®輸送型球囊擴張導管憑藉差異化產品設計及創新手術技術進一步滲透市場;及(iii)憑藉可靠的產品質量及品牌知名度,集團的彈簧圈產品在帶量採購中獲持續採用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.